Month: September 2020

TEL AVIV, Israel, Sept. 11, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT), today presents for the first time new data demonstrating ex-vivo activity of its proprietary investigational anti-MOSPD2 mAbs in patients with relapsing-remitting and progressive multiple sclerosis (MS). VBL’s study is being presented at the MS Virtual 2020, the virtual 8th Joint ACTRIMS-ECTRIMS Meeting.Data show that VBL’s anti-MOSPD2 mAbs significantly inhibited migration of monocytes isolated from all MS patients included in the study (n=33) by up to 97%, regardless of disease severity, gender or active treatment. Notably, the activity was seen not only in the monocytes from relapsing-remitting, but also those from primary progressive and secondary progressive patients with high Expanded Disability Status Scale (EDSS) scores of 5.5-6.5.“We...

PRINCETON, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate in a live Q&A at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on Friday, September 18, 2020 at 8:00 a.m. ET and host investor meetings.To access the live webcast, please visit the “Investors and News” section of the Oyster Point Pharma website at https://investors.oysterpointrx.com/.About Oyster Point PharmaOyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular...

BASKING RIDGE, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that management is scheduled to present at the HC Wainwright Virtual 22nd Annual Global Investment Conference, which is being held from September 14-16, 2020.Presentation details:Date: Wednesday, September 16, 2020Time: 1:30-1:50pm EDTA live webcast of the presentation will be available on the Investors section of the company’s website: www.electrocore.comAbout electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative...

Premium 5 is First to Market With Its Live Resin and Live Resin X Vape CartridgesRadient Adds Provincial Registrations in Alberta, Manitoba and SaskatchewanEDMONTON, Alberta, Sept. 11, 2020 (GLOBE NEWSWIRE) — Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), and Premium 5 Ltd. (“Premium 5”) are pleased to announce that the Company has successfully completed its first shipment of products to the BC Liquor Distribution Branch (the “BCLDB “), with Premium 5 products now available across British Columbia, including the first live resin based vape cartridges in Canada.Radient anticipates further purchase orders imminently, following recent completion of the provincial registration process in Alberta, Saskatchewan and Manitoba. The Company is working with additional provincial boards to register...

RALEIGH, N.C., Sept. 11, 2020 (GLOBE NEWSWIRE) — BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the presentation of five scientific posters highlighting data regarding BELBUCA at the 14th Annual PAINWeek 2020 National Conference on Pain Management taking place virtually September 11-13, 2020.Poster Presentations:A Phase I Placebo-Controlled Trial Comparing the Effect of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride: PupillometryAuthors: Lynn Webster, MD; Jacqueline Cater, PhD; Thomas Smith, MDSecondary Outcomes of a Phase I Placebo-Controlled Trial Comparing the Effect of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride on Respiratory DriveAuthors: Lynn Webster, MD; Jacqueline...

NEW YORK, Sept. 11, 2020 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020, at 2:00 p.m. ET.A live audio webcast of the discussion can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation.About Ovid TherapeuticsOvid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare...

VANCOUVER, British Columbia, Sept. 11, 2020 (GLOBE NEWSWIRE) — Juggernaut Exploration Ltd. (TSX-V: JUGR) (OTCQB: JUGRF) (FSE: 4JE) (the “Company” or “Juggernaut”) is pleased to report it has received TSX approval to earn a 100% interest in the Goldstar property announced July 7th 2020 (Link to July 7thNews) containing 238 hectares located in West Central BC in close proximity to infrastructure and the Goldstandard property providing for cost effective exploration. Shareholder approval for the issuance of greater than 10% of the issued and outstanding shares to the DSM Syndicate collectively will be sought at the Company’s AGM in December.  The Goldstar property Goldilocks Zone has provided excellent results to date containing assays of 7.86g/t AuEq over 3.75m true width. This channel was taken in 2019 over a 3.75m wide section to...

Press releaseMalmö, Sweden September 11, 2020Acarix announce final outcome in oversubscribed rights issueAcarix AB (“Acarix” or the “Company”) has completed the new share issue of a maximum of 86,156,738 shares with preferential rights for the Company’s existing shareholders, which was resolved by the extra general meeting on 11 August 2020 (the “Rights Issue”). Acarix today announces the final outcome of the Rights Issue, which shows, in line with what was communicated 9 September 2020, that the Rights Issue has been oversubscribed.The Rights Issue amounted to a maximum of approximately SEK 56 million before deduction of costs related to the Rights Issue. The final outcome shows that 70,916,535 shares, corresponding to approximately 82.3 percent of the Rights Issue, was subscribed by exercise...